Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

Summary

The purpose of the First-In-Human study was to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

Timeline

Start

2020-09-07

Primary completion

2024-09-05

Completion

2024-09-05

Outcome

Outcome not reported

Stopped (Business): “Business, strategic, and development considerations and not due to any safety concerns”

Drugs

Indications